Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 8/2012

01-08-2012 | Original Article

Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge

Authors: Xueliang Wang, Wenjie Zhang, Fen Liu, Mei Zheng, Dan Zheng, Tao Zhang, Yinglei Yi, Yahong Ding, Jian Luo, Chaoyang Dai, Hanzhong Wang, Bing Sun, Ze Chen

Published in: Archives of Virology | Issue 8/2012

Login to get access

Abstract

Our previous studies have proven the adjuvanticity of chitosan in mice when administered with inactivated and subunit influenza vaccine. In this study, we investigated the adjuvant effect of chitosan on the immunogenicity and protective efficacy of a live attenuated influenza vaccine. Mice were inoculated intranasally with live attenuated influenza vaccine plus chitosan and then challenged with a high, lethal dose of homologous or heterologous virus. Antibody responses, secretion of IFN-γ by spleen cells, body weight loss, survival rates, and residual lung virus titers were tested. The results demonstrated that live attenuated influenza vaccine with chitosan adjuvant not only protected mice completely against challenge with the homologous virus but also provided good cross-protection against a heterologous virus. In addition, chitosan as adjuvant could significantly increase the levels of antigen-specific antibodies and the population of IFN-γ-secreting T cells. These results reveal the potential of chitosan as a candidate adjuvant for use in a live attenuated influenza vaccine.
Literature
1.
Nichol KL, Treanor JJ (2006) Vaccines for seasonal and pandemic influenza. J Infect Dis 194:S111–S118PubMedCrossRef
2.
Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K et al (2000) Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181:1133–1137PubMedCrossRef
3.
Cox RJ, Brokstad KA, Ogra P (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59:1–15PubMedCrossRef
4.
Stepanova L, Naykhin A, Kolmskog C, Jonson G, Barantceva I, Bichurina M et al (2002) The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. J Clin Virol 24:193–201PubMedCrossRef
5.
Mendelman PM, Cordova J, Cho I (2001) Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 19:2221–2226PubMedCrossRef
6.
Ferko B, Kittel C, Romanova J, Sereinig S, Katinger H, Egorov A (2006) Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol 80:11621–11627PubMedCrossRef
7.
Kopecky-Bromberg SA, Fraser KA, Pica N, Carnero E, Moran TM, Franck RW et al (2009) Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 27:3766–3774PubMedCrossRef
8.
Tamura SI, Kurata T (2000) A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn J Infect Dis 53:98–106PubMed
9.
10.
Singla AK, Chawla M (2001) Chitosan: some pharmaceutical and biological aspects–an update. J Pharm Pharmacol 53:1047–1067PubMedCrossRef
11.
No HK, Meyers SP, Prinyawiwatkul W, Xu Z (2007) Applications of chitosan for improvement of quality and shelf life of foods: a review. J Food Sci 72:R87–R100PubMedCrossRef
12.
Rauw F, Gardin Y, Palya V, Anbari S, Gonze M, Lemaire S et al (2009) The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. Vet Immunol Immunop 134:249–258CrossRef
13.
Rauw F, Gardin Y, Palya V, Anbari S, Lemaire S, Boschmans M et al (2010) Improved vaccination against Newcastle disease by an in ovo recombinant HVT-ND combined with an adjuvanted live vaccine at day-old. Vaccine 28:823–833PubMedCrossRef
14.
Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L et al (2000) Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 68:5764–5770PubMedCrossRef
15.
Chang H, Li X, Teng Y, Liang Y, Peng B, Fang F et al (2010) Comparison of adjuvant efficacy of chitosan and aluminum hydroxide for intraperitoneally administered inactivated influenza H5N1 vaccine. DNA Cell Biol 29:563–568PubMedCrossRef
16.
Ghendon Y, Markushin S, Krivtsov G, Akopova I (2008) Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol 153:831–837PubMedCrossRef
17.
Ghendon Y, Markushin S, Vasiliev Y, Akopova I, Koptiaeva I, Krivtsov G et al (2009) Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J Med Virol 81:494–506PubMedCrossRef
18.
Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliver Rev 51:81–96CrossRef
19.
Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A et al (2005) Effective nasal influenza vaccine delivery using chitosan. Vaccine 23:4367–4774PubMedCrossRef
20.
Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H et al (2006) Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem Bioph Res Co 343:1124–1131CrossRef
21.
Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR (2001) Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146:2275–2289PubMedCrossRef
22.
Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 97:6108–6113PubMedCrossRef
23.
Jin H, Zhou H, Lu B, Kemble G (2004) Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60. J Virol 78:995–998PubMedCrossRef
24.
Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P et al (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 96:9345–9350PubMedCrossRef
25.
Chen J, Fang F, Li X, Chang H, Chen Z (2005) Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine 23:4322–4328PubMedCrossRef
26.
Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, Murphy BR et al (2003) Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 21:4430–4436PubMedCrossRef
27.
Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L (1998) Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16:2039–2046PubMedCrossRef
28.
McNeela EA, O’Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M et al (2000) A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19:1188–1198PubMedCrossRef
29.
Westerink MA, Smithson SL, Srivastava N, Blonder J, Coeshott C, Rosenthal GJ (2001) ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 20:711–723PubMedCrossRef
30.
Fazekas G, Rosenwirth B, Dukor P, Gergely J, Rajnavolgyi E (1994) IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol 24:3063–3067PubMedCrossRef
31.
Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A (2008) Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26:2350–2359PubMedCrossRef
32.
Szyszko E, Brokstad K, Cox RJ, Hovden AO, Madhun A, Haaheim LR (2006) Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scand J Immunol 64:467–475PubMedCrossRef
33.
Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW (2007) Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25:2085–2094PubMedCrossRef
34.
Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA et al (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13:981–990PubMedCrossRef
35.
Moran TM, Park H, Fernandez-Sesma A, Schulman JL (1999) Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 180:579–585PubMedCrossRef
36.
Sui Z, Chen Q, Fang F, Zheng M, Chen Z (2010) Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28:7690–7698PubMedCrossRef
37.
Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H et al (2010) Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol 155:535–544PubMedCrossRef
38.
Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L (1997) Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 86:509–513PubMedCrossRef
39.
Davis SS, Illum L (2003) Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 42:1107–1128PubMedCrossRef
40.
van der Lubben IM, Verhoef JC, Borchard G, Junginger HE (2001) Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14:201–207PubMedCrossRef
41.
Chen CL, Wang YM, Liu CF, Wang JY (2008) The effect of water-soluble chitosan on macrophage activation and the attenuation of mite allergen-induced airway inflammation. Biomaterials 29:2173–2182PubMedCrossRef
42.
Mori T, Murakami M, Okumura M, Kadosawa T, Uede T, Fujinaga T (2005) Mechanism of macrophage activation by chitin derivatives. J Vet Med Sci 67:51–56PubMedCrossRef
43.
Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, Azuma I (1984) Immunological activity of chitin and its derivatives. Vaccine 2:93–99PubMedCrossRef
44.
Peluso G, Petillo O, Ranieri M, Santin M, Ambrosio L, Calabro D et al (1994) Chitosan-mediated stimulation of macrophage function. Biomaterials 15:1215–1220PubMedCrossRef
45.
van Ginkel FW, Jackson RJ, Yoshino N, Hagiwara Y, Metzger DJ, Connell TD et al (2005) Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 73:6892–6902PubMedCrossRef
46.
Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T et al (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. New Engl J Med 350:896–903PubMedCrossRef
Metadata
Title
Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge
Authors
Xueliang Wang
Wenjie Zhang
Fen Liu
Mei Zheng
Dan Zheng
Tao Zhang
Yinglei Yi
Yahong Ding
Jian Luo
Chaoyang Dai
Hanzhong Wang
Bing Sun
Ze Chen
Publication date
01-08-2012
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 8/2012
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-012-1318-7

Other articles of this Issue 8/2012

Archives of Virology 8/2012 Go to the issue

Virology Division News

Mesoniviridae: a proposed new family in the order Nidovirales formed by a single species of mosquito-borne viruses

Brief Report

Molecular prevalence of bovine noroviruses and neboviruses detected in central-eastern Tunisia

Original Article

Phylogeographic analysis of avian influenza viruses isolated from Charadriiformes in Belgium confirms intercontinental reassortment in gulls

Brief Report

Molecular characterization of eight segments of Scylla serrata reovirus (SsRV) provides the complete genome sequence

Rapid Communication

Genetic reassortment between Sathuperi and Shamonda viruses of the genus Orthobunyavirus in nature: implications for their genetic relationship to Schmallenberg virus

Original Article

Novel lytic bacteriophage AB7-IBB1 of Acinetobacter baumannii: isolation, characterization and its effect on biofilm
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits